These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 34193768)

  • 1. Pharmacokinetics of primary oxidative metabolites of thalidomide in rats and in chimeric mice humanized with different human hepatocytes.
    Miura T; Uehara S; Shimizu M; Suemizu H; Yamazaki H
    J Toxicol Sci; 2021; 46(7):311-317. PubMed ID: 34193768
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of primary metabolites 5-hydroxythalidomide and 5'-hydroxythalidomide formed after oral administration of thalidomide in the rabbit, a thalidomide-sensitive species.
    Kuwagata M; Hasegawa T; Takashima H; Shimizu M; Kitajima S; Yamazaki H
    J Toxicol Sci; 2021; 46(12):553-560. PubMed ID: 34853241
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo formation of dihydroxylated and glutathione conjugate metabolites derived from thalidomide and 5-Hydroxythalidomide in humanized TK-NOG mice.
    Yamazaki H; Suemizu H; Shimizu M; Igaya S; Shibata N; Nakamura M; Chowdhury G; Guengerich FP
    Chem Res Toxicol; 2012 Feb; 25(2):274-6. PubMed ID: 22268628
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Simulation of Human Plasma Concentrations of Thalidomide and Primary 5-Hydroxylated Metabolites Explored with Pharmacokinetic Data in Humanized TK-NOG Mice.
    Nishiyama S; Suemizu H; Shibata N; Guengerich FP; Yamazaki H
    Chem Res Toxicol; 2015 Nov; 28(11):2088-90. PubMed ID: 26492539
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo formation of a glutathione conjugate derived from thalidomide in humanized uPA-NOG mice.
    Yamazaki H; Suemizu H; Igaya S; Shimizu M; Shibata N; Nakamura M; Chowdhury G; Guengerich FP
    Chem Res Toxicol; 2011 Mar; 24(3):287-9. PubMed ID: 21299192
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of pharmacokinetic profiles of lenalidomide in human plasma simulated using pharmacokinetic data in humanized-liver mice with liver toxicity detected by human serum albumin RNA.
    Murayama N; Suemizu H; Uehara S; Kusama T; Mitsui M; Kamiya Y; Shimizu M; Guengerich FP; Yamazaki H
    J Toxicol Sci; 2018; 43(6):369-375. PubMed ID: 29877213
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thalidomide and its metabolite 5-hydroxythalidomide induce teratogenicity via the cereblon neosubstrate PLZF.
    Yamanaka S; Murai H; Saito D; Abe G; Tokunaga E; Iwasaki T; Takahashi H; Takeda H; Suzuki T; Shibata N; Tamura K; Sawasaki T
    EMBO J; 2021 Feb; 40(4):e105375. PubMed ID: 33470442
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of Protein Binding of 5-Hydroxythalidomide Bioactivated in Humanized Mice with Human P450 3A-Chromosome or Hepatocytes by Two-Dimensional Electrophoresis/Accelerator Mass Spectrometry.
    Yamazaki H; Suemizu H; Kazuki Y; Oofusa K; Kuribayashi S; Shimizu M; Ninomiya S; Horie T; Shibata N; Guengerich FP
    Chem Res Toxicol; 2016 Aug; 29(8):1279-81. PubMed ID: 27464947
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thalidomide metabolism by the CYP2C subfamily.
    Ando Y; Fuse E; Figg WD
    Clin Cancer Res; 2002 Jun; 8(6):1964-73. PubMed ID: 12060642
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolic profiles of pomalidomide in human plasma simulated with pharmacokinetic data in control and humanized-liver mice.
    Shimizu M; Suemizu H; Mitsui M; Shibata N; Guengerich FP; Yamazaki H
    Xenobiotica; 2017 Oct; 47(10):844-848. PubMed ID: 27852146
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Species Specificity and Selection of Models for Drug Oxidations Mediated by Polymorphic Human Enzymes.
    Yamazaki H; Shimizu M
    Drug Metab Dispos; 2023 Jan; 51(1):123-129. PubMed ID: 35772770
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Uehara S; Murayama N; Higuchi Y; Shimizu M; Suemizu H; Guengerich FP; Yamazaki H
    Chem Res Toxicol; 2024 May; 37(5):671-674. PubMed ID: 38626399
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Synthesis and teratogenic action of n-hydroxythalidomide].
    Blaschke G; Hess HR; Lüpke NP
    Arzneimittelforschung; 1989 Mar; 39(3):293-4. PubMed ID: 2757654
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human liver microsomal cytochrome P450 3A enzymes involved in thalidomide 5-hydroxylation and formation of a glutathione conjugate.
    Chowdhury G; Murayama N; Okada Y; Uno Y; Shimizu M; Shibata N; Guengerich FP; Yamazaki H
    Chem Res Toxicol; 2010 Jun; 23(6):1018-24. PubMed ID: 20443640
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Teratogenic effects of thalidomide: molecular mechanisms.
    Ito T; Ando H; Handa H
    Cell Mol Life Sci; 2011 May; 68(9):1569-79. PubMed ID: 21207098
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human Aldehyde Oxidase 1-Mediated Carbazeran Oxidation in Chimeric TK-NOG Mice Transplanted with Human Hepatocytes.
    Uehara S; Yoneda N; Higuchi Y; Yamazaki H; Suemizu H
    Drug Metab Dispos; 2020 Jul; 48(7):580-586. PubMed ID: 32357972
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolism of thalidomide in liver microsomes of mice, rabbits, and humans.
    Lu J; Helsby N; Palmer BD; Tingle M; Baguley BC; Kestell P; Ching LM
    J Pharmacol Exp Ther; 2004 Aug; 310(2):571-7. PubMed ID: 15075384
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combining Chimeric Mice with Humanized Liver, Mass Spectrometry, and Physiologically-Based Pharmacokinetic Modeling in Toxicology.
    Yamazaki H; Suemizu H; Mitsui M; Shimizu M; Guengerich FP
    Chem Res Toxicol; 2016 Dec; 29(12):1903-1911. PubMed ID: 27337115
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human cytochrome P450 oxidation of 5-hydroxythalidomide and pomalidomide, an amino analogue of thalidomide.
    Chowdhury G; Shibata N; Yamazaki H; Guengerich FP
    Chem Res Toxicol; 2014 Jan; 27(1):147-56. PubMed ID: 24350712
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel hypothesis for thalidomide-induced limb teratogenesis: redox misregulation of the NF-kappaB pathway.
    Hansen JM; Harris C
    Antioxid Redox Signal; 2004 Feb; 6(1):1-14. PubMed ID: 14713331
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.